Tommy Gambles Awarded Breakthrough of the Year Award by TLO
Tommy Gambles, PhD, a postdoctoral research associate in Molecular Pharmaceutics at the University of Utah’s College of Pharmacy and co-founder of Thera-T Pharmaceutics, LLC, has been awarded the Technology Licensing Office’s Breakthrough of the Year Award. Gambles was recognized for his work on Multi-Antigen T-Cell Hybridizers (MATCH) technology. His development of MATCH technology marks a major advance in immunotherapy for blood cancers, targeting resistant cancer cells while reducing harmful side effects, exemplifying the bold innovation and real-world impact driving discovery at the U.
Tommy co-invented MATCH alongside Dr. Jindřich Kopeček and Jane Yang, and further advanced the platform with the development of COMPASS MATCH (COMPuter ASSisted MATCH), an AI/ML-powered dose prediction model co-created with Isaac Kendell and Richard McShinsky. This technology is a prime example of collaboration across the University, with support from the University of Utah Therapeutics Accelerator (U2TAH), and additional funding from Dr. Douglas Sborov at Huntsman Cancer Institute. Steven Valdez (Nora Eccles Harrison CVRTI) played a key role in helping launch Thera-T Pharmaceutics.
Congratulations to Tommy for the recognition!
